Optase

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for use as a lubricant to prevent further irritation and may be utilized as a protectant against additional irritation. It is also indicated for the relief of dryness of the eye.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to administer one to two drops of the medication into the affected eyes as needed. It is important to ensure that the dropper does not come into contact with the eye or any other surface to maintain sterility. The frequency of administration should be determined based on the patient's condition and response to treatment.

Contraindications

There are no specific contraindications listed for this product. However, it is imperative to seek immediate medical assistance or contact a poison control center if the product is swallowed.

Warnings and Precautions

For external use only. The solution should not be used if it changes color or becomes cloudy. To prevent contamination, it is imperative that the tip of the container does not come into contact with any surface. After each use, the cap must be securely replaced.

Healthcare professionals should advise patients to discontinue use and seek medical attention if they experience any of the following symptoms: eye pain, changes in vision, persistent redness or irritation of the eye, or if the condition worsens or lasts longer than 72 hours.

In the event of accidental ingestion, immediate medical assistance should be sought, or the patient should contact a poison control center without delay.

It is crucial for healthcare providers to monitor patients for the aforementioned symptoms and to ensure that appropriate follow-up care is provided if any adverse effects occur.

Side Effects

Patients should be aware that the product is for external use only. It is important to note that if the solution changes color or becomes cloudy, it should not be used. To prevent contamination, patients are advised not to touch the tip of the container to any surface and to replace the cap after each use.

In the event of experiencing any of the following symptoms, patients should discontinue use and consult a healthcare professional: eye pain, changes in vision, persistent redness or irritation of the eye, or if the condition worsens or lasts longer than 72 hours. These warnings are critical to ensure the safety and well-being of patients using this product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Optase (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or a poison control center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in the absence of established safety profiles. Women of childbearing potential should be counseled on the importance of effective contraception while using this medication.

Lactation

There are no specific warnings or recommendations regarding nursing mothers or lactation in the provided text. Therefore, healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication. It is advisable to monitor breastfed infants for any potential effects, although no specific concerns have been noted in the available information.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the patient's overall health status and liver function.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse effects that may arise. In the event of suspected overdosage, it is recommended to initiate supportive care and symptomatic treatment as necessary.

Healthcare providers should consider contacting a poison control center for guidance on management strategies tailored to the specific situation. Continuous assessment of the patient's clinical status is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event that the medication is swallowed, patients should be instructed to seek medical help or contact a poison control center immediately. It is essential for patients to understand the importance of these precautions to ensure their safety and the safety of others.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is crucial to store the product at a controlled temperature range of 20°C to 25°C (68°F to 77°F) to maintain its efficacy.

To ensure the integrity of the product, it must be protected from light exposure. Freezing is strictly prohibited, as it may compromise the formulation. Once opened, the product should be discarded to prevent contamination.

To avoid any risk of contamination, healthcare professionals are advised not to touch the tip of the container to any surface. After each use, it is important to securely replace the cap to maintain the product's sterility and safety.

Additional Clinical Information

The route of administration for the medication is ophthalmic, with directions for use indicating that patients should apply one or two drops in the affected eyes as needed. Clinicians should advise patients to keep the medication out of reach of children and to seek medical assistance or contact a poison control center immediately if swallowed.

Patients are cautioned that the solution is for external use only and should not be used if it changes color or becomes cloudy. To prevent contamination, it is important not to touch the tip of the container to any surface and to replace the cap after use. Patients should discontinue use and consult a doctor if they experience eye pain, changes in vision, persistent redness or irritation, or if their condition worsens or lasts more than 72 hours.

Drug Information (PDF)

This file contains official product information for Optase, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)